---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071385"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:31:19.571340+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acrivon's ACR-368 shows 35% cORR in endometrial cancer; cash $164.8M

## Summary
- Q1 2025 net loss $19.7M vs $16.5M YoY; R&D spend $15.4M on trial advancement.
- Cash, equivalents and securities $164.8M; runway into Q2 2027.
- ACR-368 Phase 2b: 35% cORR, 80% DCR in OncoSignature+ patients; 50% cORR in relapsed subset.
- ACR-2316 Phase 1: DL4 enrolling; ~25% tumor shrinkage at DL3 below projected RP2D.
- Appointed Mansoor Raza Mirza as CMO; promoted Adam Levy to CFO.

## SEC filing metadata
- accession: 0000950170-25-071385
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017025071385/0000950170-25-071385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017025071385/acrv-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071385
- JSON: https://secwatch.observer/filing/0000950170-25-071385.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.